Should I buy or sell Novan stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novan in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" NOVN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NOVN, but not buy additional shares or sell existing shares. View NOVN analyst ratings or view top-rated stocks .

How have NOVN shares performed in 2024?

Novan's stock was trading at $0.0005 at the beginning of the year. Since then, NOVN stock has increased by 60.0% and is now trading at $0.0008. View the best growth stocks for 2024 here .

How were Novan's earnings last quarter?

Novan, Inc. (NASDAQ:NOVN) issued its earnings results on Monday, May, 15th. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.32) by $0.22. The firm earned $3.17 million during the quarter, compared to the consensus estimate of $6.19 million. Novan had a negative net margin of 128.61% and a negative trailing twelve-month return on equity of 700.28%. During the same period in the prior year, the business earned ($0.71) earnings per share.

What other stocks do shareholders of Novan own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novan investors own include Bionano Genomics (BNGO) , Gran Tierra Energy (GTE) , Pennsylvania Real Estate Investment Trust (PEI) , ADMA Biologics (ADMA) , CNBX Pharmaceuticals (CNBX) , Matinas BioPharma (MTNB) , Zosano Pharma (ZSAN) , Aeterna Zentaris (AEZS) , CBL & Associates Properties (CBL) and Organigram (OGI) .

Novan (NOVN) raised $46 million in an initial public offering (IPO) on Wednesday, September 21st 2016. The company issued 3,800,000 shares at a price of $11.00-$13.00 per share. Piper Jaffray served as the underwriter for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

How do I buy shares of Novan?

Shares of NOVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:NOVN

Novan (NOVN) Stock Price, News & Analysis

→ Biden to Launch “FedNOW” [Move Your Money Now] (From Priority Gold) (Ad)

Free NOVN Stock Alerts

$0.0008

0.00 (0.00%)

(As of 04/16/2024 ET)

Compare

Today's Range: $0.0008
▼
$0.0008
50-Day Range: N/A
52-Week Range: $0.08
▼
$3.33

Volume: N/A
Average Volume: 602,421 shs
Market Capitalization: $22,412.00

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get Novan alerts:

Ad DTI

Start loving Mondays like this

Wouldn’t you love to start looking forward to Mondays? We’re in a New Paradigm Shift in the market that could make it possible! You see, rallies over the weekends have become much more common in the last few years. Imagine hitting a few buttons on your phone or laptop to place a quick trade before the weekend hits… And coming back on Monday to what could be extra income sitting in your account… Weekend after weekend!

Weekend after weekend!

About Novan Stock (NASDAQ:NOVN)

Novan, Inc., a medical dermatology company, focuses on developing and commercializing therapeutic products for skin diseases. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. The company was incorporated in 2006 and is headquartered in Durham, North Carolina.

NOVN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

NOVN Stock News Headlines

April 15, 2024 | americanbankingnews.com

StockNews.com Begins Coverage on Novan (NASDAQ:NOVN)

February 27, 2024 | wsj.com

Novartis AG

April 18, 2024 | DTI (Ad)

This company has increased its dividend every year for 54 years

There are three basic steps to building the Ultimate Dividend Portfolio. Step #1 is to Get The High Yields! So an index fund like the SPY, paying only 1.5% a year, isn’t going to cut it. But a company like Altria Group (MO) will.

February 16, 2024 | morningstar.com

Novartis AG Registered Shares

October 31, 2023 | morningstar.com

Novartis AG Registered Shares NOVN

September 8, 2023 | bizjournals.com

Novan reaches deals to sell assets in bankruptcy case

August 8, 2023 | msn.com

Firm Retention Summary: Novan

August 3, 2023 | msn.com

Novan (NOVN) Price Target Increased by 43.52% to 15.81

April 18, 2024 | DTI (Ad)

This company has increased its dividend every year for 54 years

July 17, 2023 | marketwatch.com

Novan Shares Hit 52-Week Low After Bankruptcy Declaration

June 1, 2023 | bizjournals.com

Novan cuts 50% of its workforce to extend runway

June 1, 2023 | msn.com

Novan drops 13%, will reduce workforce by 50%

May 31, 2023 | markets.businessinsider.com

Novan To "Sharpen" Focus, Resources On Berdazimer Gel

May 31, 2023 | finance.yahoo.com

Novan Focuses Strategic Direction and Announces Restructuring

May 21, 2023 | fool.com

Novan (NASDAQ: NOVN)

May 17, 2023 | msn.com

Oppenheimer Maintains Novan (NOVN) Outperform Recommendation

May 16, 2023 | finance.yahoo.com

NOVN: Counting Down to PDUFA

May 15, 2023 | finanznachrichten.de

Novan, Inc.: Novan Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 15, 2023 | markets.businessinsider.com

Novan earnings: here's what Wall Street expects

May 12, 2023 | msn.com

Earnings Preview: Novan

May 12, 2023 | msn.com

Novan Q1 2023 Earnings Preview

April 20, 2023 | finance.yahoo.com

Novan to Host Analyst and Investor Event: A Discussion of Molluscum’s Unmet Need with Pediatric Dermatologist Jeffrey Sugarman, MD, PhD

April 3, 2023 | msn.com

Novan's Return On Capital Employed Overview

March 23, 2023 | finance.yahoo.com

Novan to Report Full Year 2022 Financial Results on March 30, 2023

March 7, 2023 | finance.yahoo.com

FDA Accepts Novan’s NDA for Berdazimer Gel, 10.3% for the Treatment of Molluscum Contagiosum with a PDUFA Goal Date of January 5, 2024

October 19, 2022 | reuters.com

JPMorgan names Qian as Southeast Asia equity capital markets chief - Reuters

October 14, 2022 | finance.yahoo.com

Novan and EPI Health, a Novan Company, Announce Abstracts Accepted for Poster Presentation at the 42nd Annual Fall Clinical Dermatology Conference® - Yahoo Finance

See More Headlines

Receive NOVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novan and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 5/15/2023
Today: 4/17/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:NOVN
CUSIP: N/A
CIK: 1467154
Web: www.novan.com
Phone: (919) 485-8080
Fax: 919-237-9212
Employees: 90
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($1.32)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-31,310,000.00
Net Margins: -128.61%
Pretax Margin: -128.39%
Return on Equity: -700.28%
Return on Assets: -39.58%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.74
Quick Ratio: 0.72

Sales & Book Value

Annual Sales: $24.71 million
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.19 per share
Price / Book: 0.00

Miscellaneous

Outstanding Shares: 28,015,000
Free Float: 27,651,000
Market Cap: $22,412.00
Optionable: Not Optionable
Beta: -0.06

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Ms. Paula Brown Stafford M.P.H. (Age 58)
Pres, CEO & Chairwoman
Comp: $623.23k
Mr. John M. Gay CPA (Age 46)
CFO, Principal Accounting Officer & Corp. Sec.
Comp: $386.89k
Mr. John A. Donofrio Jr. (Age 56)
Exec. VP & COO
Comp: $602.51k
Dr. Carri Geer Ph.D.
Sr. VP & CTO
Dr. Tomoko Maeda-Chubachi M.B.A.
M.D., Ph.D., Chief Medical Officer

Key Competitors

View All Competitors

Insiders

Machelle Sanders
Sold 11,553 shares
Total: $4,736.73 ($0.41/share)

View All Insider Transactions

NOVN Stock Analysis - Frequently Asked Questions

Should I buy or sell Novan stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novan in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" NOVN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NOVN, but not buy additional shares or sell existing shares.
View NOVN analyst ratings or view top-rated stocks.
How have NOVN shares performed in 2024?: Novan's stock was trading at $0.0005 at the beginning of the year. Since then, NOVN stock has increased by 60.0% and is now trading at $0.0008.
View the best growth stocks for 2024 here.
How were Novan's earnings last quarter?: Novan, Inc. (NASDAQ:NOVN) issued its earnings results on Monday, May, 15th. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.32) by $0.22. The firm earned $3.17 million during the quarter, compared to the consensus estimate of $6.19 million. Novan had a negative net margin of 128.61% and a negative trailing twelve-month return on equity of 700.28%. During the same period in the prior year, the business earned ($0.71) earnings per share.
What other stocks do shareholders of Novan own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Novan investors own include Bionano Genomics (BNGO), Gran Tierra Energy (GTE), Pennsylvania Real Estate Investment Trust (PEI), ADMA Biologics (ADMA), CNBX Pharmaceuticals (CNBX), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Aeterna Zentaris (AEZS), CBL & Associates Properties (CBL) and Organigram (OGI).

When did Novan IPO?: Novan (NOVN) raised $46 million in an initial public offering (IPO) on Wednesday, September 21st 2016. The company issued 3,800,000 shares at a price of $11.00-$13.00 per share. Piper Jaffray served as the underwriter for the IPO and JMP Securities and Wedbush PacGrow were co-managers.
How do I buy shares of Novan?: Shares of NOVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NOVN) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial